Alaunos Therapeutics, Inc. announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 October 1, 2022. Details of the presentation are as follows: Title: Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer; Presenter: Marcelo V. Negrao, MD, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center; Date and Time:Friday, September 30, 2022, 8:30am ET; Session Title: Session 6: Cellular Therapies: Engineering T cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | +2.52% | -8.27% | +15.04% |
Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.04% | 19.05M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference